Supplementary Material

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children

Authors: Eric L. Simpson,[1]* Adelaide A. Hebert,[2] John Browning,[3] Rocco T. Serrao,[4] Howard Sofen,[5] Philip M. Brown,[6] Stephen C. Piscitelli,[6] David S. Rubenstein,[7] Anna M. Tallman[6]

Affiliations:

[1]Oregon Health & Science University, Portland, OR, USA

[2]UTHealth McGovern School of Medicine and Children's Memorial Hermann Hospital, Houston, TX, USA

[3]UT Health San Antonio, San Antonio, TX, USA

[4]Dermatologists of Southwest Ohio, Mason, OH, USA

[5]David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

[6]Dermavant Sciences, Inc., Morrisville, NC, USA

[7]Formerly of Dermavant Sciences, Inc., Morrisville, NC, USA

***Corresponding author:**

Eric L. Simpson MD, MCR, Professor of Dermatology

Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road,

Portland, OR, 97239–3098

Tel: 503-494-8311

simpsone@ohsu.edu

Supplementary Figure S1. Proposed Mechanism of Action of Tapinarof



Adapted from the Journal of the American Academy of Dermatology; 84(4); Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A; Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent; p.1065; Copyright (2021), with permission from Elsevier.

AhR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; FLG, filaggrin; HRNR, hornerin; IL, interleukin; IVL, involucrin; LOR, loricrin; Nrf2, nuclear factor erythroid 2-related factor 2; ROS, reactive oxygen species; TAP, tapinarof.

Supplementary Figure S2. ADORING 1 and 2 Trial Design



The vIGA-AD™ scale is copyright ©2017 Eli Lilly and Company – Used with permission under a Creative Commons Attribution-NoDerivatives 4.0 International License.

*A minimum of ~15% of patients were enrolled into the following age groups: 2–6 years, 7–11 years, 12–17 years, and ≥18 years. Adults (aged ≥18 years) comprised a maximum of approximately 20% of enrolled patients.

†Patients with a vIGA-AD™ score of 4 (severe) represented a minimum of ~10% of the total randomized population; the remainder had a vIGA-AD™ score of 3 (moderate).

AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; QD, once daily; R, randomized; vIGA-AD™, Validated Investigator Global Assessment for Atopic Dermatitis™.